Case and Research Letters
Scrotal Erythema: First Sign of a Cutaneous Drug Reaction to Pazopanib
Eritema escrotal como manifestación inicial de toxicodermia por pazopanib
Leído
9100
Vecesse ha leído el artículo
1952
Total PDF
7148
Total HTML
Compartir estadísticas
array:25 [ "pii" => "S1578219021000159" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.01.012" "estado" => "S300" "fechaPublicacion" => "2021-03-01" "aid" => "2506" "copyright" => "AEDV" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:277-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731020304294" "issn" => "00017310" "doi" => "10.1016/j.ad.2019.07.014" "estado" => "S300" "fechaPublicacion" => "2021-03-01" "aid" => "2506" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:277-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Eritema escrotal como manifestación inicial de toxicodermia por pazopanib" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "277" "paginaFinal" => "279" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Scrotal Erythema: First Sign of a Cutaneous Drug Reaction to Pazopanib" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1125 "Ancho" => 1500 "Tamanyo" => 190261 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Evolución: exantema maculopapuloso en el tronco y las extremidades superiores (a y b). Lesiones eritematoedematosas anulares con borde más acenudado discretamente descamativas (c). Resolución de las lesiones en tronco y extremidades a las 2 semanas de suspender el pazopanib (d y e) con mejoría de las lesiones inguinoescrotales (f).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Pons Benavent, E. Silva Díaz, S. Guillén Climent, C. Monteagudo Castro" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Pons Benavent" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Silva Díaz" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Guillén Climent" ] 3 => array:2 [ "nombre" => "C." "apellidos" => "Monteagudo Castro" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219021000159" "doi" => "10.1016/j.adengl.2021.01.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021000159?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020304294?idApp=UINPBA000044" "url" => "/00017310/0000011200000003/v1_202103020647/S0001731020304294/v1_202103020647/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219021000238" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.01.019" "estado" => "S300" "fechaPublicacion" => "2021-03-01" "aid" => "2466" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:280-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Histoid Leprosy: An Enemy Not Yet Eradicated" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "280" "paginaFinal" => "281" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Lepra histioide, un enemigo aún no erradicado" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 730 "Ancho" => 905 "Tamanyo" => 117149 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical characteristics. On the upper extremities: skin-colored papules and nodules with an infiltrated appearance, some of which are ulcerated and others with a central crust. On the lower extremities: papules coalescing to form brownish-red plaques.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "N. Calvache, D.A. Arias, V.M. Delgado" "autores" => array:3 [ 0 => array:2 [ "nombre" => "N." "apellidos" => "Calvache" ] 1 => array:2 [ "nombre" => "D.A." "apellidos" => "Arias" ] 2 => array:2 [ "nombre" => "V.M." "apellidos" => "Delgado" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731020303367" "doi" => "10.1016/j.ad.2019.07.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020303367?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021000238?idApp=UINPBA000044" "url" => "/15782190/0000011200000003/v1_202103020923/S1578219021000238/v1_202103020923/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S1578219021000160" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.01.013" "estado" => "S300" "fechaPublicacion" => "2021-03-01" "aid" => "2491" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:275-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Dermoscopic Findings in Membranous Aplasia Cutis: Differential Diagnosis to Exclude Other Forms of Focal Alopecia in Infants" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "275" "paginaFinal" => "277" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hallazgos dermatoscópicos en la aplasia cutis membranosa. Diagnóstico diferencial con otras formas de alopecia focal en lactantes" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 818 "Ancho" => 905 "Tamanyo" => 134170 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Membranous aplasia cutis congenita. Erythematous alopecic plaque with a diameter of 8 mm on the vertex of the scalp.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Morgado-Carrasco, X. Fustà-Novell" "autores" => array:2 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731020304142" "doi" => "10.1016/j.ad.2019.06.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020304142?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021000160?idApp=UINPBA000044" "url" => "/15782190/0000011200000003/v1_202103020923/S1578219021000160/v1_202103020923/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Scrotal Erythema: First Sign of a Cutaneous Drug Reaction to Pazopanib" "tieneTextoCompleto" => true "saludo" => "To the Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "277" "paginaFinal" => "279" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Pons Benavent, E. Silva Díaz, S. Guillén Climent, C. Monteagudo Castro" "autores" => array:4 [ 0 => array:4 [ "nombre" => "M." "apellidos" => "Pons Benavent" "email" => array:1 [ 0 => "martiponsbenavent@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "E." "apellidos" => "Silva Díaz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "S." "apellidos" => "Guillén Climent" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "C." "apellidos" => "Monteagudo Castro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Anatomía Patológica, Hospital Clínico Universitario de Valencia, Valencia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eritema escrotal como manifestación inicial de toxicodermia por pazopanib" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1125 "Ancho" => 1500 "Tamanyo" => 190261 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Clinical progression. Maculopapular rash on the trunk and upper limbs (A, B). Annular erythematous, edematous lesions with a more pronounced border and slight scaling (C). Resolution of lesions on the trunk and limbs within 2 weeks of interruption of pazopanib (D, E) and improvement of inguinal scrotal lesions (F).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Tyrosine kinase inhibitors (TKIs) are being increasingly used in oncology, replacing in many cases classic chemotherapy drugs. Reasons for their growing use include their superior efficacy and lower rates of adverse effects. Nonetheless, inhibition of molecular targets can result in previously undescribed adverse drug-specific reactions with an unknown etiology.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Pazopanib is a TKI indicated for the first-line treatment of advanced clear cell renal carcinoma (ccRCC) and advanced ccRCC refractory to cytokine therapy (interleukin-2 or interferon-α). It is also indicated for adults with certain subtypes of metastatic soft-tissue sarcoma that are refractory to chemotherapy or that have progressed within 12 months of adjuvant or neoadjuvant chemotherapy.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> The drug exerts a powerful inhibitory effect on vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and the stem cell factor receptor c-KIT.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> A range of cutaneous adverse effects have been described for pazopanib, including hair depigmentation, alopecia, and nonspecific rashes.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">We report what is, to our knowledge, the first case of scrotal erythema associated with the use of pazopanib.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Case report. A 66-year-old man with a history of diabetes and metastatic ccRCC under treatment with pazopanib for 3 months presented with well-circumscribed erythematous, scaling plaques of 1 month’s duration in the inguinal scrotal area (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A, B). Bacterial and fungal cultures were negative. Histologic examination of a biopsy specimen showed psoriasiform dermatitis with exocytosis of neutrophils into the epidermis (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>C, D). Despite treatment with oral antihistamines and oral and topical corticosteroids, the lesions spread to the trunk and upper and lower extremities (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>A–C). Given the worsening of the lesions and their significant effect on the patient’s quality of life and failure to respond to treatment, it was decided to interrupt treatment with pazopanib. This resulted in significant clinical improvement, with resolution of practically all the lesions (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>D, E). The scrotal lesions were the last to clear (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>F). Based on the clinical and histologic findings and the improvement observed following withdrawal of pazopanib, the diagnosis was TKI-induced toxic drug eruption.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Targeted therapy drugs can cause cutaneous adverse effects. The effects caused by TKIs are quite specific and are characterized by highly variable clinical manifestations and in most cases are dependent on dose and treatment duration.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Scrotal erythema is an uncommon cutaneous reaction consisting of well-circumscribed pruritic erythematous plaques, generally located in the scrotal area, although they can spread to the rest of the genital area, including the groin. Scrotal erythema has been described in patients treated with sorafenib, sunitinib, and cabozantinib,<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> but this is the first time it has been reported for pazopanib. The only specific changes reported by the few histopathologic studies that have investigated scrotal erythema are acanthosis and parakeratosis.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a> The pathogenic mechanisms are unknown, although it has been postulated that VEGF-induced neovascularization and increased vascular permeability and hypoxia-inducible factor 1α may have an important role; nonetheless, as well known, the administration of VEGF inhibitors involves a feedback mechanism that results in increased plasma and tissue VEGF levels.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Scrotal erythema is one of the lesser common cutaneous adverse effects described for TKIs. Lee et al.,<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> in a series of 109 patients treated with sorafenib, reported adverse effect rates of 48% for palmoplantar reactions, 26% for alopecia and stomatitis, and 1.83% for scrotal erythema.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> In a series of 41 patients treated with cabozantinib, Zuo et al.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> reported rates of 54% for palmoplantar reactions, 44% for hair depigmentation, 20% for xerosis, and 15% for scrotal erythema or ulceration. Iacovelli et al.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> also described a case of vulvar pruritus and pain associated with local erythema following the administration of sunitinib.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">The diagnosis of scrotal erythema is essentially clinical, and it is important to be familiar with this entity to ensure correct diagnosis and appropriate treatment. Proposed treatments include physical measures to reduce skin friction and pressure, barrier creams and ointments,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> and as a last alternative, dose fractionation or reduction, or, if this fails, temporary interruption.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a> Scrotal erythema frequently recurs after reintroduction of the drug, requiring thus in some cases definitive interruption.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> A range of conditions including trauma, infection, inflammation, and tumors should be contemplated in the differential diagnosis, in particular allergic or irritant contact dermatitis, atopic dermatitis, psoriasis, certain ichthyoses, Bowen disease, extramammary Paget disease, and dermatophytosis.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> It is also important to rule out red scrotum syndrome, a chronic disease of unknown etiology that follows a similar course to scrotal erythema. Histologically, it shows telangiectasias without a significant inflammatory infiltrate, findings that correspond to erythromelalgia- or rosacea-like neurogenic vasodilation.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Diagnosis is established by ruling out all other possibilities. Red scrotum syndrome requires specific treatment; oral carvedilol and topical timolol have been shown to be effective.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> Other treatments, including topical calcineurin inhibitors, oral doxycycline, and oral gabapentin, have been used, but with less success.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">More studies are needed to study the correlation between the administration of pazopanib and the appearance of scrotal erythema. Proper clinical follow-up and treatment is also needed to prevent dose reductions and treatment interruptions, but these are sometimes the only options for patients who develop toxic drug reactions.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0040" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2019-05-17" "fechaAceptado" => "2019-07-16" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Pons Benavent M, Silva Díaz E, Guillén Climent S, Monteagudo Castro C. Eritema escrotal como manifestación inicial de toxicodermia por pazopanib. Actas Dermosifiliogr. 2021;112:277–279.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1239 "Ancho" => 1500 "Tamanyo" => 449893 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical and histologic findings. A, Erythematous plaque with well-defined borders in the pubic area. B, Scrotal erythematous plaque affecting both sides of the groin area, with a more pronounced erythematous scaling border. C, Epidermal acanthosis with extensive parakeratosis and a perivascular lymphocytic infiltrate (hematoxylin-eosin, original magnification ×200). D, Epidermal acanthosis with neutrophilic spongiosis and perivascular lymphocytic dermal infiltrates with eosinophils (hematoxylin-eosin, original magnification ×200).</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1125 "Ancho" => 1500 "Tamanyo" => 190261 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Clinical progression. Maculopapular rash on the trunk and upper limbs (A, B). Annular erythematous, edematous lesions with a more pronounced border and slight scaling (C). Resolution of lesions on the trunk and limbs within 2 weeks of interruption of pazopanib (D, E) and improvement of inguinal scrotal lesions (F).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Skin problems and EGFR-tyrosine kinase inhibitor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "T. Kokuki" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jjco/hyv207" "Revista" => array:6 [ "tituloSerie" => "Jpn J Clin Oncol." "fecha" => "2016" "volumen" => "46" "paginaInicial" => "291" "paginaFinal" => "298" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26826719" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Votrient®. Ficha técnica del medicamento. Centro de información online de medicamentos de la Agencia Europea del Medicamento (EMA). Available from <a target="_blank" href="http://www.ema.europa.eu">http://www.ema.europa.eu</a> [Accessed 3 April 2019]." ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reacciones capilares de las nuevas terapias dirigidas contra el cáncer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.F. Mir-Bonafé" 1 => "D. Saceda-Corralo" 2 => "S. Vañó-Galván" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2018.10.019" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr." "fecha" => "2019" "volumen" => "110" "paginaInicial" => "181" "paginaFinal" => "256" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30704627" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W.J. Lee" 1 => "J.L. Lee" 2 => "S.E. Chang" 3 => "M.W. Lee" 4 => "Y.K. Yang" 5 => "J.H. Choi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09290.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2009" "volumen" => "161" "paginaInicial" => "1045" "paginaFinal" => "1051" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19558553" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.C. Zuo" 1 => "A.B. Apolo" 2 => "J.J. DiGiovanna" 3 => "H.L. Parnes" 4 => "C.M. Keen" 5 => "S. Nanda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamadermatol.2014.2734" "Revista" => array:6 [ "tituloSerie" => "JAMA Dermatol." "fecha" => "2015" "volumen" => "151" "paginaInicial" => "170" "paginaFinal" => "177" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25427282" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sunitinib-induced scrotal cutaneous side-effect" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.Y. Chou" 1 => "K.H. Wang" 2 => "Y.H. Lin" 3 => "Y.T. Lin" 4 => "H.H. Tsai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1346-8138.2012.01681.x" "Revista" => array:6 [ "tituloSerie" => "J Dermatol." "fecha" => "2012" "volumen" => "40" "paginaInicial" => "67" "paginaFinal" => "68" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23078345" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Scrotal cutaneous side effects of sunitinib" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B. Billemont" 1 => "S. Barete" 2 => "O. Rixe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc0802736" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med." "fecha" => "2008" "volumen" => "359" "paginaInicial" => "975" "paginaFinal" => "976" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18753659" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R. Iacovelli" 1 => "M.L. Mancini" 2 => "E. Risi" 3 => "A. Palazzo" 4 => "E. Cortesi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2011.05057.x" "Revista" => array:6 [ "tituloSerie" => "Int. J. Dermatol." "fecha" => "2012" "volumen" => "51" "paginaInicial" => "221" "paginaFinal" => "222" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22250635" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Managing red scrotum syndrome (RSS) with topical timolol" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T.M. Pyle" 1 => "W.R. Heymann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ijd.14463" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol." "fecha" => "2019" "volumen" => "58" "paginaInicial" => "e162" "paginaFinal" => "e163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31034585" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carvedilol for the treatment of red scrotum syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Merhi" 1 => "N. Ayoub" 2 => "M. Mrad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jdcr.2017.06.021" "Revista" => array:6 [ "tituloSerie" => "JAAD Case Rep." "fecha" => "2017" "volumen" => "3" "paginaInicial" => "464" "paginaFinal" => "466" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28936473" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011200000003/v1_202103020923/S1578219021000159/v1_202103020923/en/main.assets" "Apartado" => array:4 [ "identificador" => "6157" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case and Research Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011200000003/v1_202103020923/S1578219021000159/v1_202103020923/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021000159?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 14 | 5 | 19 |
| 2024 Octubre | 164 | 48 | 212 |
| 2024 Septiembre | 204 | 24 | 228 |
| 2024 Agosto | 278 | 62 | 340 |
| 2024 Julio | 204 | 41 | 245 |
| 2024 Junio | 155 | 36 | 191 |
| 2024 Mayo | 112 | 49 | 161 |
| 2024 Abril | 125 | 32 | 157 |
| 2024 Marzo | 157 | 30 | 187 |
| 2024 Febrero | 199 | 35 | 234 |
| 2024 Enero | 176 | 37 | 213 |
| 2023 Diciembre | 223 | 11 | 234 |
| 2023 Noviembre | 393 | 60 | 453 |
| 2023 Octubre | 342 | 20 | 362 |
| 2023 Septiembre | 270 | 37 | 307 |
| 2023 Agosto | 229 | 26 | 255 |
| 2023 Julio | 230 | 34 | 264 |
| 2023 Junio | 167 | 28 | 195 |
| 2023 Mayo | 277 | 32 | 309 |
| 2023 Abril | 155 | 31 | 186 |
| 2023 Marzo | 170 | 37 | 207 |
| 2023 Febrero | 133 | 25 | 158 |
| 2023 Enero | 87 | 32 | 119 |
| 2022 Diciembre | 98 | 41 | 139 |
| 2022 Noviembre | 94 | 47 | 141 |
| 2022 Octubre | 154 | 42 | 196 |
| 2022 Septiembre | 119 | 70 | 189 |
| 2022 Agosto | 71 | 56 | 127 |
| 2022 Julio | 67 | 51 | 118 |
| 2022 Junio | 47 | 41 | 88 |
| 2022 Mayo | 128 | 58 | 186 |
| 2022 Abril | 149 | 43 | 192 |
| 2022 Marzo | 179 | 64 | 243 |
| 2022 Febrero | 168 | 37 | 205 |
| 2022 Enero | 198 | 57 | 255 |
| 2021 Diciembre | 171 | 42 | 213 |
| 2021 Noviembre | 136 | 55 | 191 |
| 2021 Octubre | 129 | 79 | 208 |
| 2021 Septiembre | 98 | 61 | 159 |
| 2021 Agosto | 111 | 39 | 150 |
| 2021 Julio | 93 | 23 | 116 |
| 2021 Junio | 177 | 41 | 218 |
| 2021 Mayo | 68 | 40 | 108 |
| 2021 Abril | 112 | 101 | 213 |
| 2021 Marzo | 71 | 63 | 134 |
| 2021 Febrero | 36 | 24 | 60 |
| 2021 Enero | 10 | 5 | 15 |
Mostrar todo
